Rexahn Pharmaceuticals (RNN) Announces Earnings Results, Hits Expectations

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) released its quarterly earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.17), Fidelity Earnings reports.

Shares of NYSEAMERICAN:RNN traded up $0.01 during midday trading on Tuesday, hitting $1.16. The company had a trading volume of 900 shares, compared to its average volume of 271,651. Rexahn Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.70.

A number of brokerages have commented on RNN. HC Wainwright set a $17.00 price objective on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research report on Monday. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $1.25 price objective on the stock in a research report on Tuesday, October 23rd. B. Riley set a $8.00 price objective on Rexahn Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 2nd. Finally, Ifs Securities upgraded Rexahn Pharmaceuticals from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, October 4th.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/11/06/rexahn-pharmaceuticals-rnn-announces-earnings-results-hits-expectations.html.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

Further Reading: Trading Strategy Methods for Individual Investors

Earnings History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply